Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort

Anthony J Swerdlow, Rosie Cooke, Dominique Beckers, Gary Butler, Jean-Claude Carel, Stefano Cianfarani, Peter Clayton, Joël Coste, Annalisa Deodati, Emmanuel Ecosse, Anita CS. Hokken-Koelega, Aysha J Khan, Wieland Kiess, Claudia E. Kuehni, Christa E. Flück, Roland Pfaffle, Lars Sävendahl, Grit Sommer, Muriel Thomas, Anders Tidblad, Sally Tollerfield, Gladys RJ. Zandwijken

The Journal of Clinical Endocrinology & Metabolism
Endocrine Society

Submitted: May 24, 2018
Accepted: August 14, 2018
First Online: August 17, 2018

The Journal of Clinical Endocrinology & Metabolism; Copyright 2018 DOI: 10.1210/jc.2018-01133

Meningioma risk after growth hormone.

Risk of meningioma in European patients treated with growth hormone in childhood: results from the SAGhE cohort

Anthony J Swerdlow[1,2], Rosie Cooke[1], Dominique Beckers[3,4], Gary Butler[5,6], Jean-Claude Carel[7,8], Stefano Cianfarani [9,10], Peter Clayton[11,12], Joël Coste[13,14], Annalisa Deodati[9], Emmanuel Ecosse[13,14], Anita CS. Hokken-Koelega[15,16], Aysha J Khan[11,12], Wieland Kiess[17], Claudia E. Kuehni[18], Christa E. Flück[19], Roland Pfaffle[17], Lars Sävendahl[10], Grit Sommer[18], Muriel Thomas[4], Anders Tidblad[10], Sally Tollerfield[5], Gladys RJ. Zandwijken[15,16].

[1] *Institute of Cancer Research, Division of Genetics and Epidemiology, London, SM2 5NG, UK*

[2] *Institute of Cancer Research, Division of Breast Cancer Research, London, SW7 3RP, UK*

[3] *Unite d'Endocrinologie Pédiatrique, CHU UCL NAMUR, Yvoir, 5530, Belgium*

[4] *Belgian Society for Pediatric Endocrinology and Diabetology (BESPEED), 1200, Brussels, Belgium.*

[5] *UCL Institute of Child Health, London, WCiN 1EH, UK*

[6] *University College London Hospitals NHS Foundation Trust, London, NW1 2PG, UK*

[7] *Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Universitaire Robert-Debré, Department of Pediatric Endocrinology and Diabetology, and Centre de Référence des Maladies Endocriniennes Rares de la Croissance F-75019, Paris, France*

[8] *PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, F-75019 Paris, France*

[9] *Dipartimento Pediatrico Universitario Ospedaliero "Bambino Gesù" Children's Hospital-Tor Vergata University, 00165-Rome, Italy*

[10] *Department of Women's and Children's Health, Karolinska Institutet, SE-141 86, Stockholm, Sweden.*

[11] *Royal Manchester Children's Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, M13 9WL, UK*

[12] *Developmental Biology & Medicine, Faculty of Biology, Medicine & Health, University of Manchester, Manchester, M13 9PL, UK*

[13] *Biostatistics and Epidemiology Unit and Approches Psychologiques et Epidémiologiques des Maladies Chroniques Equipe d'Accueil 4360, Paris, France*

[14] *Groupe Hospitalier Cochin-Saint Vincent de Paul and University Paris Descartes, 75014 Paris, France*

[15] *Dutch Growth Research Foundation, Westzeedijk 106, 3016 AH Rotterdam, the Netherlands*

[16] *Erasmus Medical Center/Sophia Children's Hospital, Wytemaweg 80, 3015 CN Rotterdam, the Netherlands*

[17] *Hospital for Children and Adolescents and Centre of Pediatric Research, University of Leipzig, Liebigstr. 20a, D-04103 Leipzig, Germany*

[18] *Institute of Social and Preventive Medicine, University of Bern, Finkenhubelweg 11, 3012 Bern, Switzerland*

[19] *Division of Paediatric Endocrinology, Diabetology & Metabolism, University Children's Hospital Bern, Inselspital, 3010 Bern, Switzerland*

ORCiD numbers:

0000-0001-5550-4159

SWERDLOW

Received 24 May 2018. Accepted 14 August 2018.

Context: There has been concern that growth hormone (GH) treatment of children might increase meningioma risk. Results of published studies have been inconsistent and limited.
Objective: To examine meningioma risks in relation to GH treatment.
Design: Cohort study with follow-up via cancer registries and other registers.
Setting: Population-based.
Patients: A cohort of 10,403 patients treated in childhood with recombinant GH (r-hGH) in 5 European countries since this treatment was first used in 1984. Expected rates from national cancer registration statistics.
Main Outcome Measures: Risk of meningioma incidence.
Results: During follow-up 38 meningiomas occurred. Meningioma risk was greatly raised in the cohort overall (SIR=75.4; 95% confidence interval (CI) 54.9-103.6), as a consequence of high risk in subjects who had received radiotherapy for underlying malignancy (SIR= 658.4; 95% CI 460.4-941.7). Risk was not significantly raised in patients who did not receive radiotherapy. Risk in radiotherapy-treated patients was not significantly related to mean daily dose of GH, duration of GH treatment or cumulative dose of GH.
Conclusions: Our data add to evidence of very high risk of meningioma in patients treated in childhood with GH after cranial radiotherapy, but suggest that GH may not affect radiotherapy-related risk, and that there is no material raised risk of meningioma in GH-treated patients who did not receive radiotherapy.

In a 5-country cohort of 10,403 patients treated with recombinant growth hormone, meningioma risk was greatly raised in relation to radiotherapy, but not apparently related to growth hormone.

Introduction

Since 1957 growth hormone (GH) has been used to treat GH deficiency and short stature, initially using a human pituitary extract (p-hGH) but since 1985 using solely recombinant growth hormone (r-hGH).

GH causes increased serum concentrations of insulin-like growth factor 1 (IGF-1). IGF-1 is antiapoptotic and mitogenic in vitro, and levels in adults have been associated in several studies with risks of subsequent malignancies(1). As a consequence, and because of early case-reports and some findings in humans, there has been concern as to whether or not GH therapy might increase cancer risks(1, 2).

Meningiomas express GH receptors, and in vitro activation of the GH/IGF-1 axis increases the growth rate of meningiomas(3). In an in vivo model, downregulation of the GH/IGF-1 axis reduced meningioma growth(4). In the US Childhood Cancer Survivors Study cohort, second malignancy was significantly more common among GH-treated than non GH-treated patients, and meningioma was much the most common second malignancy in the GH-treated group, accounting for 40% of all second neoplasms(5). A UK study(6) found meningiomas more common in GH-treated brain-irradiated cancer patients than in matched brain-irradiated cancer controls, but based on small numbers, and a later analysis from the US cohort did not find raised meningioma risk(7). The published results, however, have been based on relatively small numbers – 338 GH-treated patients in the US study(7) and 110 in the only other analysis, in the UK(6). To analyse the risk with much greater power, we therefore analysed

meningioma risks in the Safety and Appropriateness of Growth Hormone Treatments in Europe (SAGhE) study, a large cross-European cohort study of patients treated with r-GH since 1984.

Materials and Methods

The SAGhE study is a coordinated cohort study in eight European countries of patients treated with r-hGH at paediatric ages since such treatment was first used (1984-6, depending on the country), and never treated with p-hGH. Details of the assembly of the cohort and methods of data collection have been described previously(8). Ethics committee agreement was obtained in every country and for each patient either written informed consent was obtained, or the ethics committee stated that consent was not required. Only three patients in the cohort died from meningioma during follow-up, so we have only undertaken incidence analyses, not mortality analyses, for meningioma in this paper. Cancer incidence follow-up was via cancer registration and highly complete in Belgium, the Netherlands, Sweden, Switzerland and the UK, and therefore analyses of incidence are restricted to these countries. The cohorts were national and population-based, or virtually so, in Belgium, the Netherlands, Sweden and the UK and clinic-based and sub-national in (Switzerland). We obtained data on demographic and GH-related variables from existing databases and from case-notes. Subjects were followed for mortality via national population-based registries in Belgium, the Netherlands, Sweden and the UK, and by municipal registers and other means in Switzerland. In all countries, follow-up was independent of pharmaceutical companies and in all countries the study was conducted with appropriate ethics committee agreement. Vital status follow-up was highly complete. We excluded from analysis, individuals with certain conditions that both lead to GH therapy and are themselves very strong predisposing factors for malignancy (e.g. Type 1 neurofibromatosis, Fanconi syndrome(9)). In addition, we also excluded from the cohort, subjects (n=1) whose original diagnosis leading to growth hormone treatment was meningioma.

We calculated person-years at risk of meningioma in the cohort by sex, 5 year age-group, single calendar year, and country, commencing on the date of first treatment with GH and ending at whichever occurred earliest of: diagnosis of meningioma, death, loss to follow-up, or a fixed end-date for each country (the date to which follow-up in that country was considered complete at the time the follow-up data were obtained). In Switzerland, cancer incidence follow-up was censored at age 16 or 21, depending on the canton, because cancer incidence data were from the Swiss Childhood Cancer Registry which only covered these ages.

Meningiomas were taken as tumours coded to ICD10 codes C70 (malignant), D32 (benign) and D42 (uncertain and unknown behaviour) (WHO, 1992), and equivalents in ICD 9. Observed numbers of cancers and deaths in the cohort were compared with expectations derived from application of sex, age, country and year specific rates in the general population of each country to the person-years at risk in these categories in the cohort, to provide standardised incidence ratios (SIRs). Absolute excess rates (AERs) were calculated by subtracting expected from observed numbers of cases, dividing by person-years at risk and multiplying by 10,000. Trends in risk with variables such as duration of GH treatment were tested as described by Breslow and Day(10); p values are all 2-sided.

As well as analyses of risks in the cohort overall, we also analysed the data in subdivisions by initial diagnosis, whether radiotherapy was received, and cumulative dose, mean daily dose, and duration of GH treatment. To be able to explore potential surveillance bias in the diagnosis of meningiomas in the cohort, we endeavoured to discover from clinical sources for each UK patient, the pathway that had led to diagnosis of the meningioma.

Results

Of 10,786 patients recorded as treated with r-hGH in the five study countries, 257 had to be excluded from analysis because of lack of permission for cancer incidence follow-up or lack of data, and 126 because of an underlying diagnosis at high risk of cancer or an underlying diagnosis of meningioma as the reason for GH treatment. This left 10,403 who formed the study cohort. Just over half were male and four fifths were aged 5-14 years at first treatment (Table 1). The most common underlying diagnoses were isolated growth failure (n= 3,952), and malignancy (n= 1,830).

During follow-up 326 patients died, 175 were lost to follow-up, 38 were diagnosed with meningioma (30 benign, 1 malignant, and 7 of uncertain behaviour), and 9,864 survived without meningioma to the end of the follow-up period. A total of 154,795 person-years at risk were accrued, an average of 14.9 years per patient. The SIR for meningioma in the cohort overall was 75.4 (95% CI54.9-103.6) (Table 2), and the AER was 2.4 per 10,000 (not in Table). Relative risks were similar in males and females, and greatly raised in the Netherlands, Sweden and the UK. There were no cases in Belgium and Switzerland but expecteds were small (0.04 and 0.01 respectively) and 95% CIs included the all-country SIR. All but one of the meningiomas occurred in patients whose initial diagnosis was cancer (SIR=466.3 (95% CI 337.8-643.5)); the risk was not significantly raised in patients whose initial diagnosis was not cancer (SIR=2.4 (95% CI 0.3-16.7)). Risks were over 300-fold raised for patients whose initial diagnoses were CNS tumour, haematological malignancy, or non-CNS solid tumour (Table 2).

We had information that 1,178 of the patients had received cranio(-spinal) radiotherapy (all but 13 for cancer), 3,055 had not received cranio(-spinal) radiotherapy, and for 6,170 this was not known. Thirty of the 38 meningiomas occurred in the cancer patients known to have received cranio(-spinal) radiotherapy (Table 3). The relative risk of meningioma for cancer patients treated with radiotherapy was over 600 (Table 3). The SIR was not related to age at first GH treatment time since starting treatment, or attained age. There were also no significant trends in risk with mean daily GH dose duration of treatment, and cumulative dose of GH. Of the remaining meningioma cases, 7 occurred in patients with unknown radiotherapy status (SIR=277.5 (95% CI 132.3-582.1); all were in Sweden, for which the databases used for this study did not include data on radiotherapy to allow them to be included in risk analyses, but on separate enquiry four had received prior radiotherapy and for three no information on this was available. One meningioma occurred among patients without radiotherapy (a patient with Turner syndrome), for whom risk was not significantly raised.

Of the 22 meningiomas diagnosed incident in patients in the UK, we were able to obtain information on the events leading to diagnosis for 14; of these; 9 were diagnosed after symptomatic presentations and 5 at routine follow-up.

Discussion

Our analysis of over 10,000 patients treated with GH in childhood showed meningioma risk over 70-fold, highly significantly, raised in this cohort compared with general population expectations. This was a consequence of a risk six times greater than this in the subset of patients who had received GH after treatment for cancer, and within these, greater risk again in the patients who had received cranio(-spinal) radiotherapy. Although we do not have data on radiotherapy dose, incidence of GH deficiency after cranial radiotherapy is dose and time dependent(11-13) and most of the cancer patients had brain tumours, which are usually treated

with 40-50 Gy(11), so we would expect that radiotherapy doses in the cohort will generally have been ≥40 Gy.

The relative risks in our cohort for meningioma are far larger than for any other tumour after GH treatment(9). Since ionizing radiation exposure is a well-established cause of meningioma(14, 15), including after radiation therapy of childhood cancers(16, 17), the extraordinarily large risk in our GH-treated cohort does not in itself incriminate GH. Comparisons of follow-up of GH-treated and untreated cancer patients in the US and UK(5, 6) have given some evidence of raised risk of meningioma associated with GH, although a later analysis from the US cohort(7) did not find raised risk. Our study had the weakness that we were not able to compare risks in our GH cohort directly with untreated patients, since we did not have data on such patients. On the other hand, our study had the strength that we were able, unlike previous studies, to analyse risks in relation to dose and duration of GH treatment – critical variables in assessing whether there is an aetiological relationship(18). These GH variables were not significantly related to meningioma risk and furthermore there was no significant raised risk of meningioma in the 8,573 non-cancer patients in our cohort who received GH therapy. Thus our data, based on different variables and a far larger cohort than previously, do not support the hypothesis that GH treatment influences meningioma risk. We were not able to collect IGF1 data for the cohort, but future research would be improved by investigating, if practical, whether IGF1 levels during GH treatment relate to subsequent meningioma risk. We were also not able to analyse meningioma risks in relation to extent of, or treatment for, other pituitary deficiencies, but these seem unlikely to explain the meningioma risk in these patients since the majority of cases did not have a record of other pituitary deficiencies and only thirteen had a record of treatment for such deficiencies.

The main reason for the raised meningioma risk in the cohort is likely to be ionising radiation exposure. Previous cohort studies of meningioma risk after radiation exposure have found excess relative risks (ERRs) per Gy ranging from 0.64 to 5.1, with a summary ERR across studies of 1.81(15). Our relative risks are of the same order as those for ≥40 Gy exposures to the meninges in a large UK childhood cancer cohort(16), but several times larger than those found in a similar US cohort(17).

Meningioma is a tumour for which there is known to be a high prevalence of subclinical disease: on brain MRI in the general population, 0.5% of individuals aged 45-59 (the youngest ages studied) had incidental findings of meningioma(19). There is therefore considerable scope for intensive medical contacts and cerebral imaging (especially MRI) consequent on underlying cerebral malignancies and GH treatment in our cohort to lead to diagnosis of asymptomatic meningiomas that would not otherwise have been detected, or at least not at that time. Such a 'screening' effect, if there is one, might be expected to operate particularly around (or indeed before) the time of first treatment with GH, when prevalent asymptomatic meningiomas incident over many years previously might come to light, and to diminish subsequently, when only newly incident cases would be available for detection. Our data, however, did not show diminishing risks with longer time since first treatment. Furthermore, among the UK cases for whom we could identify the pathway to diagnosis, most of the tumours were investigated because of symptoms (although we cannot tell, of course, whether these symptoms would not have been presented, or not have been investigated further, if the patient had not had a previous cerebral tumour and GH treatment).

A more subtle screening effect might have occurred if improvements in imaging technology over time had caused detection of some meningiomas in the cohort in recent years

that were already present but undetected at the time of earlier, lower sensitivity, imaging(6). This could have led to artefactual raised risks throughout follow-up; we do not have data to measure the extent, if any, of such an effect.

In conclusion, our data add to evidence of the very high relative risks of meningioma in patients treated in childhood with r-hGH after cranial radiotherapy for malignancy. Clinically it is important to be aware of this risk when following-up such patients. Our data and the previous literature on radiation effects indicate that the raised risk is mainly due to radiotherapy, although it may also to some extent reflect detection of asymptomatic meningiomas as a consequence of intensive medical surveillance and cerebral imaging in these patients. Our data also suggest, however, that GH treatment has not augmented further the radiotherapy-related risk.

Acknowledgements

We gratefully acknowledge the assistance in all countries of the GH patients and their families. We also thank: in Belgium, Colienne de la Barre, Christine Derycke, Siska Verlinde for collecting and verifying data, the members of the Belgian Society for Pediatric Endocrinology and Diabetology (BESPEED, previously BSGPE), L van Eycken and the persons of the Belgian Cancer Registry, the persons of the National Population Registry, the Federal and Regional Death Registries for their essential contribution sharing their data with us, and Professor Marc Maes; in France, Caroline Arnaud-Sarthou, Vean-Eng Ly, Florentia Kaguelidou and Fabienne Landier for their invaluable contributions. Members of the French SAGhE study steering committee, Michel Andrejak (CHU d'Amiens), Juliette Bloch (IVS), Anne Castot (AFSSAPS), Jean-Louis Chaussain (Académie de Médecine), Dominique Costagliola (INSERM), Nathalie Hoog-Labouret (INCa), Carmen Kreft-Jaïs (AFSSAPS), Anne Périllat (DGS), Béatrice Porokhov (AFSSAPS), Catherine Rey-Quinio (AFSSAPS). We thank all the physicians involved in the follow-up of patients and in the review process at Association France Hypophyse and, in particular, those who contributed to the collection of data for the study; in Germany, the physicians and nurses caring for the GH patients and their families, and Mandy Vogel, Leipzig; in Italy, Flavia Pricci, Rome; Cristina Fazzini, Rome; Pietro Panei, Rome; Giuseppe Scirè, Rome; Gian Luigi Spadoni, Rome; Franco Cavallo, Torino; Patrizia Matarazzo, Torino; Gianluca Aimaretti, Torino; Laura Perrone, Napoli; in the Netherlands, we thank Sandra de Zeeuw for verifying data. We thank the members of the Dutch Growth Hormone Advisory Board of the Dutch Society for Paediatrics and all paediatric endocrinologists of the Advisory Group Growth Hormone involved in GH treatment of children. We also thank registration teams of the Comprehensive Cancer Centre of the Netherlands and Comprehensive Cancer Centre South for the collection of data for the Netherlands Cancer Registry and also the scientific staff of the Comprehensive Cancer Centre of the Netherlands ; in Sweden, the statistician team led by Nils-Gunnar Pehrsson, the Board of the National Growth Hormone Registry; Kerstin Albertsson-Wikland, Stefan A Aronson, Peter Bang, Jovanna Dahlgren, Maria Elfving, Jan Gustafsson, Lars Hagenäs, Anders Häger, Sten A Ivarsson, Berit Kriström, Claude Marcus, Christian Moell, Karl Olof Nilsson, Svante Norgren, Martin Ritzen, Johan Svensson, Torsten Tuvemo, Ulf Westgren, Otto Westphal, Jan Åman, and all paediatric endocrinologists and paediatricians involved in the GH treatment of children for their assistance in collecting and verifying data; in Switzerland, Rahel Kuonen, Bern; U. Eiholzer, Zurich; J. Girard, Basel; S. Gschwendt, Zug; M. Hauschild, Lausanne; M. Janner, Bern; B. Kuhlmann, Aarau; D. L'Allemand, St. Gallen; U. Meinhardt, Zurich; P-E. Mullis, Bern; F. Phan-Hug, Lausanne; E. Schoenle, Zurich; M. Steigert; Chur; U. Zumsteg, Basel; R. Zurbruegg, Bienne; in the UK, the members of the British Society for Paediatric Endocrinology and Diabetes in the 21 historic UK Growth centres for tracking down

and contacting former and current patients, in particular; Justin Davies, Southampton; Jo Blair, Liverpool; Fiona Ryan, Oxford; Liz Crowne, Bristol; Savitha Shenoy, Leicester; Carlo Acerini, Cambridge; Jeremy Kirk, Birmingham; Tim Cheetham, Newcastle; Leo Dunkel, London Barts; Tabitha Randell, Nottingham; Sabah Alvi, Leeds; Neil Wright, Sheffield; Justin Warner, Cardiff; Amalia Mayo, Aberdeen; Guftar Shaikh, Glasgow; Louise Bath, Edinburgh; the Medicines for Children Research Network and the Scottish Medicines for Children Network who supported the network of research nurses; the former Pfizer UK KIGS team for assistance in making electronic database records of treated patients available to the local investigators at each of the UK Growth Centres, and Sharon Squires, London.

Funding

We thank and acknowledge funding for SAGhE in all countries from the European Union (HEALTH-F2-2009-223497); in addition, there was funding in Belgium from the Belgian Study Group for Paediatric Endocrinology (BSGPE); in France, the Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS, the French drug safety agency), Direction Générale de la Santé (DGS, French Ministry of Health), Institut National du Cancer (INCa); in Sweden, from the Swedish Research Council, Regional University Hospital Grants (ALF), the Swedish Cancer Society, and the Swedish Childhood Cancer Foundation; and in Switzerland from the Swiss Cancer League (KLS-02586-02-2010; KLS-2948-02-2012), Pfizer AG, Novo Nordisk Pharma AG, Sandoz Pharmaceuticals AG; and in the UK, UCL, from the UK Child Growth Foundation.

The European Union, HEALTH-F2-2009-223497, Jean-Claude Carel; The Belgian Study Group for Paediatric Endocrinology (BSGPE), Not Applicable; The Agence Française de Sécurité Sanitaire des Produits de Santé (AFSSAPS, the French drug safety agency), Jean-Claude Carel; Direction Générale de la Santé (DGS, French Ministry of Health), Jean-Claude Carel; Institut National du Cancer (INCa), Jean-Claude Carel; The Swedish Research Council, Lars Sävendahl; The Swedish Cancer Society, Lars Sävendahl; The Swedish Childhood Cancer Foundation, Lars Sävendahl; The Swiss Cancer League, (KLS-02586-02-2010; KLS-2948-02-2012), Claudia E Kuehni; Pfizer AG, Claudia E Kuehni; Novo Nordisk Pharma AG, Claudia E Kuehni; Sandoz Pharmaceuticals AG, Claudia E Kuehni; The UK Child Growth Foundation, Gary Butler; Regional University Hospital Grants (ALF), Lars Sävendahl

Corresponding author and person to whom reprint requests should be addressed: Professor Anthony Swerdlow, DSc, Division of Genetics and Epidemiology, Sir Richard Doll Building, Institute of Cancer Research, Sutton, Surrey SM2 5NG, UK. (Telephone: +44 (0) 208 722 4012; fax: +44 (0) 208 722 4019; email: anthony.swerdlow@icr.ac.uk)

Disclosure summary:
PC is a consultant for MerckSerono. LS is a member of the NordiNet International Study Committee (Novo Nordisk) and recipient of investigator-initiated independent research awards from MerckSerono (GGI award), NovoNordisk and Pfizer, and lecture honoraria from Ferring, Novo Nordisk, Pfizer, and Merck Serono. J-CC is an investigator in clinical trials using GH sponsored by Pfizer and by Lilly and in post-marketing studies using several brands of GH, support for travel to international meetings from several GH manufacturers. SC has received lecture fees from Ipsen, Merck-Serono, Novo Nordisk and Pfizer, research grants from Merck

Serono, Eli Lilly and Pfizer, support for travel to international meetings from several GH manufacturers and is member of PRISM advisory board (Ipsen). WK is a member of the Novo Nordisk Advisory Board on GH treatment, and has received lecture and consultancy honoraria from Pfizer, Ipsen and Sandoz. ACSH-K is a member of the Pfizer KIGS Steering Committee, Novo Nordisk Advisory Board on GH treatment and recipient of investigator-initiated independent research grants from Novo Nordisk and Pfizer and lecture fees from Novo Nordisk, Sandoz and Pfizer.

References

1. Clayton PE, Banerjee I, Murray PG, Renehan AG. Growth hormone, the insulin-like growth factor axis, insulin and cancer risk. Nat Rev Endocrinol 2011;**7**(1):11-24.
2. Swerdlow AJ. Does growth hormone therapy increase the risk of cancer? Nat Clin Pract Endocrinol Metab 2006;**2**(10):530-1.
3. Friend KE, Radinsky R, McCutcheon IE. Growth hormone receptor expression and function in meningiomas: effect of a specific receptor antagonist. J Neurosurg 1999;**91**(1):93-9.
4. McCutcheon IE, Flyvbjerg A, Hill H, Li J, Bennett WF, Scarlett JA, Friend KE. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001;**94**(3):487-92.
5. Ergun-Longmire B, Mertens AC, Mitby P, Qin J, Heller G, Shi W, Yasui Y, Robison LL, Sklar CA. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab 2006;**91**(9):3494-8.
6. Mackenzie S, Craven T, Gattamaneni HR, Swindell R, Shalet SM, Brabant G. Long-term safety of growth hormone replacement after CNS irradiation. J Clin Endocrinol Metab 2011;**96**(9):2756-61.
7. Patterson BC, Chen Y, Sklar CA, Neglia J, Yasui Y, Mertens A, Armstrong GT, Meadows A, Stovall M, Robison LL, Meacham LR. Growth hormone exposure as a risk factor for the development of subsequent neoplasms of the central nervous system: a report from the childhood cancer survivor study. J Clin Endocrinol Metab 2014;**99**(6):2030-7.
8. Swerdlow AJ, Cooke R, Albertsson-Wikland K, Borgstrom B, Butler G, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse E, Gausche R, Giacomozzi C, Kiess W, Hokken-Koelega AC, Kuehni CE, Landier F, Maes M, Mullis PE, Pfaffle R, Savendahl L, Sommer G, Thomas M, Tollerfield S, Zandwijken GR, Carel JC. Description of the SAGhE Cohort: A Large European Study of Mortality and Cancer Incidence Risks after Childhood Treatment with Recombinant Growth Hormone. Horm Res Paediatr 2015;**84**(3):172-83.
9. Swerdlow AJ, Cooke R, Beckers D, Borgstrom B, Butler G, Carel JC, Cianfarani S, Clayton P, Coste J, Deodati A, Ecosse E, Gausche R, Giacomozzi C, Hokken-Koelega ACS, Khan AJ, Kiess W, Kuehni CE, Mullis PE, Pfaffle R, Savendahl L, Sommer G, Thomas M, Tidblad A, Tollerfield S, Van Eycken L, Zandwijken GRJ. Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. J Clin Endocrinol Metab 2017;**102**(5):1661-72.
10. Breslow NE, Day NE. Statistical methods in cancer research. Volume I - The analysis of case-control studies. IARC Sci Publ 1980(32):5-338.
11. Darzy KH. Radiation-induced hypopituitarism after cancer therapy: who, how and when to test. Nat Clin Pract Endocrinol Metab 2009;**5**(2):88-99.
12. Clayton PE, Shalet SM. Dose dependency of time of onset of radiation-induced growth hormone deficiency. J Pediatr 1991;**118**(2):226-8.

13. Rappaport R, Brauner R. Growth and endocrine disorders secondary to cranial irradiation. Pediatr Res 1989;**25**(6):561-7.
14. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol 2010;**99**(3):307-14.
15. Braganza MZ, Kitahara CM, Berrington de Gonzalez A, Inskip PD, Johnson KJ, Rajaraman P. Ionizing radiation and the risk of brain and central nervous system tumors: a systematic review. Neuro Oncol 2012;**14**(11):1316-24.
16. Taylor AJ, Little MP, Winter DL, Sugden E, Ellison DW, Stiller CA, Stovall M, Frobisher C, Lancashire ER, Reulen RC, Hawkins MM. Population-based risks of CNS tumors in survivors of childhood cancer: the British Childhood Cancer Survivor Study. J Clin Oncol 2010;**28**(36):5287-93.
17. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ, Hammond S, Yasui Y, Kasper CE, Mertens AC, Donaldson SS, Meadows AT, Inskip PD. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006;**98**(21):1528-37.
18. Bradford Hill. The Environment and Disease: Association or Causation? Proceedings of the Royal Society of Medicine 1965;**58**:295-300.
19. Vernooij MW, Ikram MA, Tanghe HL, Vincent AJ, Hofman A, Krestin GP, Niessen WJ, Breteler MM, van der Lugt A. Incidental findings on brain MRI in the general population. N Engl J Med 2007;**357**(18):1821-8.

Table 1. Descriptive characteristics of patients in the SAGhE cohort followed for risk of meningioma

Characteristic		**No.**	**%**
Sex	Male	5530 4517	53.2
	Female	4873 3825	46.8
Country	Belgium	1325	12.7
	Netherlands	1685	16.2
	Sweden	2822	27.1
	Switzerland	737	7.1
	UK	3834	36.9
Age started GH treatment (years)	0-4	1130	10.9
	5-9	3632	34.9
	10-14	4834	46.5
	15-19	807	7.8
Year started GH treatment	<1990	2070	19.9
	1990-94	3976	38.2
	1995-99	2840	27.3
	≥2000	1517	14.6
Diagnosis leading to GH treatment	CNS tumour	1307	12.6
	Non CNS solid tumour	97	0.9
	Hematological malignancy	426	4.1
	Chronic renal failure and renal diseases renrenal diseases diseases	139	1.3
	Turner syndrome	1721	16.5
	Other syndromes and chronic diseases	1003	9.6
	Multiple pituitary hormone deficiency organic GHD	1343	12.9
	Skeletal dysplasias	286	2.8
	Isolated growth failure[a]	3952	38.0
	Non-classifiable	129	1.2
Total		**10403**	**100.0**

[a]Including isolated growth hormone deficiency, idiopathic short stature, and small for gestational age.

Table 2. Risk of meningioma in the cohort in relation to sex, country of residence, and initial diagnosis leading to GH treatment

	All initial diagnoses		Initial diagnosis cancer		Initial diagnosis non-cancer	
	n	**SIR (95% CI)**	**n**	**SIR (95% CI)**	**n**	**SIR (95% CI)**
Sex						
Male	18	83.7 (52.7, 132.8)***	18	464.9 (292.9, 737.8)***	0	0.0 (0.0, 20.5)
Female	20	69.2 (44.7, 107.3)***	19	467.6 (298.3, 733.1)***	1	4.0 (0.6, 28.6)
Country of residence						
Belgium	0	0.0 (0.0, 92.2)	0	0.0 (0.0, 368.9)	0	0.0 (0.0, 92.2)
Netherlands	9	84.4 (43.9, 162.2)***	9	503.4 (261.9, 967.5)***	0	0.0 (0.0, 41.0)
Sweden	7	40.5 (19.3, 85.0)***	7	385.6 (183.8, 808.8)***	0	0.0 (0.0, 24.6)
Switzerland	0	0.0 (0.0, 368.9)	0	0.0 (0.0, 6148.1)	0	0.0 (0.0, 368.9)
UK	22	126.8 (83.5, 192.6)***	21	593.5 (387.0, 910.3)***	1	7.2 (1.0, 51.4)
Diagnosis leading to GH treatment						
CNS tumour	29	533.7 (370.9, 768.0)***	29	533.7 (370.9, 768.0)***	-	-
Haematological malignancy	7	319.2 (152.2, 669.5)***	7	319.2 (152.2, 669.5)***	-	-
Non-CNS solid tumour	1	324.1 (45.6, 2300.6)**	1	324.1 (45.6, 2300.6)**	-	-
Turner syndrome	1	9.2 (1.3, 65.0)*	-	-	1	9.2 (1.3, 65.0)*
Isolated growth failure	0	0.0 (0.0, 19.4)	-	-	0	0.0 (0.0, 19.4)
Other non-cancer	0	0.0 (0.0, 30.7)	-	-	0	0.0 (0.0, 30.7)
Total	**38**	**75.4 (54.9, 103.6)*** **	**37**	**466.3 (337.8, 643.5)*** **	**1**	**2.4 (0.3, 16.7)**

SIR= Standardised incidence ratio; CI= confidence interval; GH= Growth hormone; CNS= central nervous system
* p<0.05
** p<0.01
*** p<0.001

Table 3. Risk of meningioma in patients whose initial diagnosis was cancer and were treated by radiotherapy, by age and GH treatment variables

		n	**SIR (95% CI)**
Age started GH treatment (years)	0-4	1	1401.5 (197.4, 9949.0)**
	5-9	9	782.4 (407.1, 1503.7)***
	10-14	19	644.7 (411.2, 1010.7)***
	15-19	1	258.1 (36.4, 1832.1)**
	p trend		0.21
Time since started GH treatment (years)	0-4	2	338.0 (84.5, 1351.4)***
	5-9	2	197.5 (49.4, 789.5)***
	10-14	14	1130.7 (669.7, 1909.2)***
	15-19	10	857.0 (461.1, 1592.8)***
	≥20	2	365.8 (91.5, 1462.5)***
	p trend		0.26
Attained age (years)	0-9	0	0.0 (0.0, 12296.3)
	10-19	6	487.2 (218.9, 1084.3)***
	20-29	21	863.5 (563.0, 1324.4)***
	≥30	3	346.7 (111.8, 1074.8)***
	p trend		0.95
Duration of GH treatment (years)	<3	8	547.5 (273.8, 1094.7)***
	3-5	11	587.3 (325.3, 1060.5)***
	≥6	11	998.9 (553.2, 1803.8)***
	p trend		0.19
Mean GH dose (µg/kg/day)	<20	7	635.1 (302.8, 1332.2)***
	20-9	17	805.4 (500.7, 1295.6)***
	30-9	3	425.1 (137.1, 1318.1)***
	≥40	1	1297.5 (182.8, 9210.9)**
	p trend		0.92
Cumulative GH dose (mg/kg)	<25	8	511.9 (256.0, 1023.7)***
	25-49	10	601.3 (323.6, 1117.6)***

	50-99	11	1286.0 (712.2, 2322.1)***
	≥100	0	0.0 (0.0, 4098.8)
	p trend		0.13
Total		30	658.4 (460.4, 941.7)***

SIR= Standardised incidence ratio; CI= Confidence interval; GH= Growth hormone

* p<0.05

** p<0.01

*** p<0.001